Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part voluntarily and sign a consent form
• People aged 18 to 75 years old
• People whose doctors expect them to live for at least 3 more months
• People who are generally able to care for themselves and carry out light activity (a standard measure of physical functioning, scored 0–1 on a scale used by doctors)
• People who have been diagnosed with cervical cancer or endometrial cancer that has come back or spread, confirmed by lab testing of tissue or cell samples
• People who are able to provide a stored tumour tissue sample from the last 3 years, for testing including a marker called PD-L1
• People who have at least one area of cancer that can be measured on scans, according to standard medical guidelines
• People whose liver, kidney, blood, and other organ functions meet the levels required by the trial
• People whose side effects from any previous cancer treatment have largely resolved to a mild level or lower
• Women who could become pregnant must have a negative pregnancy test within 7 days before starting treatment, must not be breastfeeding, and must use reliable barrier contraception during treatment and for 6 months after it ends

Who may not be able to join:

• People who have previously been treated with a certain type of targeted drug called an ADC that uses a topoisomerase I inhibitor, or that targets EGFR and/or HER3
• People who received chemotherapy, biological therapy, or immunotherapy within 4 weeks (or 5 half-lives of the drug, whichever is shorter) before starting the trial
• People in certain parts of the trial (Stage II, excluding a specific group called Cohort 1) who have already received any systemic cancer treatment
• People who experienced a serious immune-related side effect (Grade 3 or higher) from previous immunotherapy, or an immune-related heart inflammation of Grade 2 or higher
• People who used immune-modifying medications within 14 days before starting the trial
• People who needed ongoing steroid medication throughout their whole body within 2 weeks before starting the trial
• People with a history of serious heart or stroke-related conditions
• People with active autoimmune or inflammatory diseases
• People who had another type of cancer that was growing or being treated within the past 3 years
• People with a history of lung inflammation (ILD or pneumonitis) that required steroid treatment, or who currently have active lung inflammation
• People whose high blood pressure is not well controlled and requires two or more blood pressure medications
• People whose diabetes is not well controlled
• People who had a serious blood clot event requiring treatment within 6 months before joining
• People whose cancer has spread to and is currently active in the brain or spinal cord
• People with significant or poorly controlled fluid build-up in body cavities (such as around the lungs or abdomen)
• People who have had an allergic reaction to similar types of antibody-based medicines or to ingredients in the trial drug
• People who have had an organ transplant or a bone marrow transplant using donor cells
• People who test positive for HIV, or who have active tuberculosis, active hepatitis B, or active hepatitis C
• People who currently have an infection that requires treatment throughout the whole body
• People who have taken part in another clinical trial within 4 weeks before starting this one
• People whose scans show the cancer is growing into or wrapping around major blood vessels in the abdomen, chest, neck, or throat
• People who have serious wounds, ulcers, or bone fractures that have not healed within 4 weeks before signing the consent form
• People who have had significant bleeding or a clear tendency to bleed within 4 weeks before signing the consent form
• People who have received or are planning to receive a live vaccine within 28 days before joining the trial
• People with a history of serious neurological or psychiatric conditions
• People the trial investigators consider unsuitable for any other reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.